Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Danger of Herbal Tea: A Case of Acute Cholestatic Hepatitis Due to Artemisia annua Tea.

Ruperti-Repilado FJ, Haefliger S, Rehm S, Zweier M, Rentsch KM, Blum J, Jetter A, Heim M, Leuppi-Taegtmeyer A, Terracciano L, Bernsmeier C.

Front Med (Lausanne). 2019 Oct 11;6:221. doi: 10.3389/fmed.2019.00221. eCollection 2019.

2.

Dopaminergic D1 Receptor Stimulation Affects Effort and Risk Preferences.

Soutschek A, Gvozdanovic G, Kozak R, Duvvuri S, de Martinis N, Harel B, Gray DL, Fehr E, Jetter A, Tobler PN.

Biol Psychiatry. 2019 Sep 12. pii: S0006-3223(19)31670-1. doi: 10.1016/j.biopsych.2019.09.002. [Epub ahead of print]

PMID:
31668477
3.

Intracavitary cisplatin-fibrin chemotherapy after surgery for malignant pleural mesothelioma: A phase I trial.

Opitz I, Lauk O, Meerang M, Jetter A, Aeschlimann B, Seifert B, Günther D, Stahel RA, Weder W.

J Thorac Cardiovasc Surg. 2019 Aug 22. pii: S0022-5223(19)31613-7. doi: 10.1016/j.jtcvs.2019.07.073. [Epub ahead of print]

PMID:
31590949
4.

Interprofessional and interdisciplinary collaboration for early phase oncological clinical trials in academia-Myo-inositoltrispyrophophate as model.

Grossmann R, Schneider MA, Linecker M, Lehn JM, Nicolau C, Traber M, Tay F, Vicente D, Jetter A, Mollet A, Szucs T, Graf R, Clavien PA, Limani P.

Pharmacol Res. 2019 Apr 19:104238. doi: 10.1016/j.phrs.2019.04.022. [Epub ahead of print] Review. No abstract available.

PMID:
31009662
5.

Drugs and hepatic transporters: A review.

Jetter A, Kullak-Ublick GA.

Pharmacol Res. 2019 Apr 17:104234. doi: 10.1016/j.phrs.2019.04.018. [Epub ahead of print] Review.

PMID:
31004787
6.

JDDG Leser in Mosambik.

Jetter A.

J Dtsch Dermatol Ges. 2019 Apr;17(4):476. doi: 10.1111/ddg.13817. No abstract available.

PMID:
30958925
7.

Severe reduction in tacrolimus concentrations with concomitant metamizole (dipyrone) therapy in transplant patients.

Sigaroudi A, Jetter A, Mueller TF, Kullak-Ublick G, Weiler S.

Eur J Clin Pharmacol. 2019 Jun;75(6):869-872. doi: 10.1007/s00228-019-02635-y. Epub 2019 Jan 29. No abstract available.

PMID:
30694339
8.

Do clinical and laboratory parameters predict thiopurine metabolism and clinical outcome in patients with inflammatory bowel diseases?

Frick S, Müller D, Kullak-Ublick GA, Jetter A.

Eur J Clin Pharmacol. 2019 Mar;75(3):335-342. doi: 10.1007/s00228-018-02616-7. Epub 2019 Jan 4.

PMID:
30610277
9.

Risk Factors for Higher-than-Expected Residual Rivaroxaban Plasma Concentrations in Real-Life Patients.

Kaserer A, Schedler A, Jetter A, Seifert B, Spahn DR, Stein P, Studt JD.

Thromb Haemost. 2018 May;118(5):808-817. doi: 10.1055/s-0038-1639585. Epub 2018 Apr 3.

PMID:
29614520
10.

Delayed Sputum Culture Conversion in Tuberculosis-Human Immunodeficiency Virus-Coinfected Patients With Low Isoniazid and Rifampicin Concentrations.

Sekaggya-Wiltshire C, von Braun A, Lamorde M, Ledergerber B, Buzibye A, Henning L, Musaazi J, Gutteck U, Denti P, de Kock M, Jetter A, Byakika-Kibwika P, Eberhard N, Matovu J, Joloba M, Muller D, Manabe YC, Kamya MR, Corti N, Kambugu A, Castelnuovo B, Fehr JS.

Clin Infect Dis. 2018 Aug 16;67(5):708-716. doi: 10.1093/cid/ciy179.

11.

Development of OXY111A, a novel hypoxia-modifier as a potential antitumor agent in patients with hepato-pancreato-biliary neoplasms - Protocol of a first Ib/IIa clinical trial.

Limani P, Linecker M, Kron P, Samaras P, Pestalozzi B, Stupp R, Jetter A, Dutkowski P, Müllhaupt B, Schlegel A, Nicolau C, Lehn JM, Petrowsky H, Humar B, Graf R, Clavien PA.

BMC Cancer. 2016 Oct 19;16(1):812.

12.

Assessment of CYP1A2 enzyme activity in relation to type-2 diabetes and habitual caffeine intake.

Urry E, Jetter A, Landolt HP.

Nutr Metab (Lond). 2016 Oct 6;13:66. eCollection 2016.

13.

A case-control field study on the relationships among type 2 diabetes, sleepiness and habitual caffeine intake.

Urry E, Jetter A, Holst SC, Berger W, Spinas GA, Langhans W, Landolt HP.

J Psychopharmacol. 2017 Feb;31(2):233-242. doi: 10.1177/0269881116668595. Epub 2016 Sep 27.

PMID:
27649774
14.

No major effects of vitamin D3 (1,25 dihydroxyvitamin D3) on absorption and pharmacokinetics of folic acid and fexofenadine in healthy volunteers.

Kullak-Ublick GA, Gubler C, Spanaus K, Ismair MG, Claro da Silva T, Jetter A.

Eur J Clin Pharmacol. 2016 Jul;72(7):797-805. doi: 10.1007/s00228-016-2050-0. Epub 2016 Mar 29.

15.

Anatomic Single-Graft Anterior Cruciate Ligament Reconstruction Restores Rotational Stability: A Robotic Study in Cadaveric Knees.

Harms SP, Noyes FR, Grood ES, Jetter AW, Huser LE, Levy MS, Gardner EJ.

Arthroscopy. 2015 Oct;31(10):1981-90. doi: 10.1016/j.arthro.2015.04.081. Epub 2015 May 29.

PMID:
26033460
16.

Effect of anteromedial and posterolateral anterior cruciate ligament bundles on resisting medial and lateral tibiofemoral compartment subluxations.

Gardner EJ, Noyes FR, Jetter AW, Grood ES, Harms SP, Levy MS.

Arthroscopy. 2015 May;31(5):901-10. doi: 10.1016/j.arthro.2014.12.009. Epub 2015 Feb 4.

PMID:
25661860
17.

Anterior cruciate ligament function in providing rotational stability assessed by medial and lateral tibiofemoral compartment translations and subluxations.

Noyes FR, Jetter AW, Grood ES, Harms SP, Gardner EJ, Levy MS.

Am J Sports Med. 2015 Mar;43(3):683-92. doi: 10.1177/0363546514561746. Epub 2014 Dec 24.

PMID:
25540296
18.

Urinary excretion of melatonin and association with breast cancer: meta-analysis and review of the literature.

Basler M, Jetter A, Fink D, Seifert B, Kullak-Ublick GA, Trojan A.

Breast Care (Basel). 2014 Jul;9(3):182-7. doi: 10.1159/000363426.

19.

Treatment of gout in a renal transplant patient leading to severe thrombocytopenia.

Weiler S, Aellig N, Fauchère I, Jetter A, Corti N.

J Clin Pharm Ther. 2014 Oct;39(5):571-2. doi: 10.1111/jcpt.12190. Epub 2014 Jul 11.

PMID:
25040676
20.

Impact of variable CYP genotypes on breast cancer relapse in patients undergoing adjuvant tamoxifen therapy.

Mwinyi J, Vokinger K, Jetter A, Breitenstein U, Hiller C, Kullak-Ublick GA, Trojan A.

Cancer Chemother Pharmacol. 2014 Jun;73(6):1181-8. doi: 10.1007/s00280-014-2453-5. Epub 2014 Mar 29.

21.

Pharmacokinetics of oral vitamin D(3) and calcifediol.

Jetter A, Egli A, Dawson-Hughes B, Staehelin HB, Stoecklin E, Goessl R, Henschkowski J, Bischoff-Ferrari HA.

Bone. 2014 Feb;59:14-9.

PMID:
24516879
22.

Pharmacokinetics of daily daptomycin in critically ill patients undergoing continuous renal replacement therapy.

Corti N, Rudiger A, Chiesa A, Marti I, Jetter A, Rentsch K, Müller D, Béchir M, Maggiorini M.

Chemotherapy. 2013;59(2):143-51. doi: 10.1159/000353400. Epub 2013 Sep 18.

23.

Low allopurinol doses are sufficient to optimize azathioprine therapy in inflammatory bowel disease patients with inadequate thiopurine metabolite concentrations.

Curkovic I, Rentsch KM, Frei P, Fried M, Rogler G, Kullak-Ublick GA, Jetter A.

Eur J Clin Pharmacol. 2013 Aug;69(8):1521-31. doi: 10.1007/s00228-013-1500-1. Epub 2013 Apr 16.

24.

Novel coagulation factor concentrates: issues relating to their clinical implementation and pharmacokinetic assessment for optimal prophylaxis in haemophilia patients.

Ljung R, Auerswald G, Benson G, Jetter A, Jiménez-Yuste V, Lambert T, Morfini M, Remor E, Sørensen B, Salek SZ.

Haemophilia. 2013 Jul;19(4):481-6. doi: 10.1111/hae.12094. Epub 2013 Feb 6. Review.

PMID:
23387528
25.

Clinical usefulness of electronic drug-drug interaction checking in the care of cardiovascular surgery inpatients.

Taegtmeyer AB, Kullak-Ublick GA, Widmer N, Falk V, Jetter A.

Cardiology. 2012;123(4):219-22. doi: 10.1159/000343272. Epub 2012 Nov 27.

26.

Bilberry ingestion improves disease activity in mild to moderate ulcerative colitis - an open pilot study.

Biedermann L, Mwinyi J, Scharl M, Frei P, Zeitz J, Kullak-Ublick GA, Vavricka SR, Fried M, Weber A, Humpf HU, Peschke S, Jetter A, Krammer G, Rogler G.

J Crohns Colitis. 2013 May;7(4):271-9. doi: 10.1016/j.crohns.2012.07.010. Epub 2012 Aug 9.

PMID:
22883440
27.

Oral supplementation with 25(OH)D3 versus vitamin D3: effects on 25(OH)D levels, lower extremity function, blood pressure, and markers of innate immunity.

Bischoff-Ferrari HA, Dawson-Hughes B, Stöcklin E, Sidelnikov E, Willett WC, Edel JO, Stähelin HB, Wolfram S, Jetter A, Schwager J, Henschkowski J, von Eckardstein A, Egli A.

J Bone Miner Res. 2012 Jan;27(1):160-9. doi: 10.1002/jbmr.551.

28.

Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens.

Wyen C, Hendra H, Siccardi M, Platten M, Jaeger H, Harrer T, Esser S, Bogner JR, Brockmeyer NH, Bieniek B, Rockstroh J, Hoffmann C, Stoehr A, Michalik C, Dlugay V, Jetter A, Knechten H, Klinker H, Skaletz-Rorowski A, Fätkenheuer G, Egan D, Back DJ, Owen A; German Competence Network for HIV/AIDS Coordinators.

J Antimicrob Chemother. 2011 Sep;66(9):2092-8. doi: 10.1093/jac/dkr272. Epub 2011 Jun 29.

29.

Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide.

Tomalik-Scharte D, Fuhr U, Hellmich M, Frank D, Doroshyenko O, Jetter A, Stingl JC.

Drug Metab Dispos. 2011 May;39(5):927-32. doi: 10.1124/dmd.110.036921. Epub 2011 Jan 26.

PMID:
21270106
30.

Optimized intrapleural cisplatin chemotherapy with a fibrin carrier after extrapleural pneumonectomy: a preclinical study.

Opitz I, Erne BV, Demirbas S, Jetter A, Seifert B, Stahel R, Weder W.

J Thorac Cardiovasc Surg. 2011 Jan;141(1):65-71. doi: 10.1016/j.jtcvs.2010.09.032.

31.

Do activities of cytochrome P450 (CYP)3A, CYP2D6 and P-glycoprotein differ between healthy volunteers and HIV-infected patients?

Jetter A, Fätkenheuer G, Frank D, Klaassen T, Seeringer A, Doroshyenko O, Kirchheiner J, Hein W, Schömig E, Fuhr U, Wyen C.

Antivir Ther. 2010;15(7):975-83. doi: 10.3851/IMP1648.

32.

Assessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphan.

Abduljalil K, Frank D, Gaedigk A, Klaassen T, Tomalik-Scharte D, Jetter A, Jaehde U, Kirchheiner J, Fuhr U.

Clin Pharmacol Ther. 2010 Nov;88(5):643-51. doi: 10.1038/clpt.2010.137. Epub 2010 Sep 29.

33.

Pharmacogenetics of drug-induced liver injury.

Russmann S, Jetter A, Kullak-Ublick GA.

Hepatology. 2010 Aug;52(2):748-61. doi: 10.1002/hep.23720. Review.

PMID:
20607838
34.

[Interactions with antiretroviral drugs].

Ceschi A, Curkovic I, Kirchheiner J, Kullak-Ublick GA, Jetter A.

Internist (Berl). 2010 Jan;51(1):94-9. doi: 10.1007/s00108-009-2528-2. German.

35.

The role of human CYP2C8 and CYP2C9 variants in pioglitazone metabolism in vitro.

Muschler E, Lal J, Jetter A, Rattay A, Zanger U, Zadoyan G, Fuhr U, Kirchheiner J.

Basic Clin Pharmacol Toxicol. 2009 Dec;105(6):374-9. doi: 10.1111/j.1742-7843.2009.00457.x. Epub 2009 Jul 15.

36.

Effect of ritonavir on the pharmacokinetics of the benzimidazoles albendazole and mebendazole: an interaction study in healthy volunteers.

Corti N, Heck A, Rentsch K, Zingg W, Jetter A, Stieger B, Pauli-Magnus C.

Eur J Clin Pharmacol. 2009 Oct;65(10):999-1006. doi: 10.1007/s00228-009-0683-y. Epub 2009 Jun 27.

PMID:
19562329
37.

Plasma 4beta-hydroxycholesterol: an endogenous CYP3A metric?

Tomalik-Scharte D, Lütjohann D, Doroshyenko O, Frank D, Jetter A, Fuhr U.

Clin Pharmacol Ther. 2009 Aug;86(2):147-53. doi: 10.1038/clpt.2009.72. Epub 2009 May 20.

PMID:
19458613
38.

In vivo role of cytochrome P450 2E1 and glutathione-S-transferase activity for acrylamide toxicokinetics in humans.

Doroshyenko O, Fuhr U, Kunz D, Frank D, Kinzig M, Jetter A, Reith Y, Lazar A, Taubert D, Kirchheiner J, Baum M, Eisenbrand G, Berger FI, Bertow D, Berkessel A, Sörgel F, Schömig E, Tomalik-Scharte D.

Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):433-43. doi: 10.1158/1055-9965.EPI-08-0832. Epub 2009 Feb 3.

39.

Phenotyping of N-acetyltransferase type 2 and xanthine oxidase with caffeine: when should urine samples be collected?

Jetter A, Kinzig M, Rodamer M, Tomalik-Scharte D, Sörgel F, Fuhr U.

Eur J Clin Pharmacol. 2009 Apr;65(4):411-7. doi: 10.1007/s00228-008-0597-0. Epub 2008 Dec 13.

40.

Mesalazine pharmacokinetics and NAT2 phenotype.

Lück H, Kinzig M, Jetter A, Fuhr U, Sörgel F.

Eur J Clin Pharmacol. 2009 Jan;65(1):47-54. doi: 10.1007/s00228-008-0550-2. Epub 2008 Aug 14.

41.

[Pharmacogenetics in oncology: 5-fluorouracil and the dihydropyrimidine dehydrogenase].

Lazar A, Jetter A.

Dtsch Med Wochenschr. 2008 Jul;133(28-29):1501-4. doi: 10.1055/s-2008-1081098. Review. German.

PMID:
18597209
42.

No role for the CYP3A5*3 polymorphism in intestinal and hepatic metabolism of midazolam.

Tomalik-Scharte D, Doroshyenko O, Kirchheiner J, Jetter A, Lazar A, Klaassen T, Frank D, Wyen C, Fätkenheuer G, Fuhr U.

Eur J Clin Pharmacol. 2008 Oct;64(10):1033-5. doi: 10.1007/s00228-008-0503-9. Epub 2008 Jun 28. No abstract available.

43.

Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients.

Wyen C, Hendra H, Vogel M, Hoffmann C, Knechten H, Brockmeyer NH, Bogner JR, Rockstroh J, Esser S, Jaeger H, Harrer T, Mauss S, van Lunzen J, Skoetz N, Jetter A, Groneuer C, Fätkenheuer G, Khoo SH, Egan D, Back DJ, Owen A; German Competence Network for HIV/AIDS.

J Antimicrob Chemother. 2008 Apr;61(4):914-8. doi: 10.1093/jac/dkn029. Epub 2008 Feb 14.

44.

Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients.

Wyen C, Fuhr U, Frank D, Aarnoutse RE, Klaassen T, Lazar A, Seeringer A, Doroshyenko O, Kirchheiner JC, Abdulrazik F, Schmeisser N, Lehmann C, Hein W, Schömig E, Burger DM, Fätkenheuer G, Jetter A.

Clin Pharmacol Ther. 2008 Jul;84(1):75-82. doi: 10.1038/sj.clpt.6100452. Epub 2008 Jan 9.

45.

Assessment of urinary mephenytoin metrics to phenotype for CYP2C19 and CYP2B6 activity.

Klaassen T, Jetter A, Tomalik-Scharte D, Kasel D, Kirchheiner J, Jaehde U, Fuhr U.

Eur J Clin Pharmacol. 2008 Apr;64(4):387-98. Epub 2007 Dec 11.

46.

The effect of silymarin on oral nifedipine pharmacokinetics.

Fuhr U, Beckmann-Knopp S, Jetter A, Lück H, Mengs U.

Planta Med. 2007 Nov;73(14):1429-35. Epub 2007 Oct 30.

PMID:
17968815
47.

Novel mutations of the extraneuronal monoamine transporter gene in children and adolescents with obsessive-compulsive disorder.

Lazar A, Walitza S, Jetter A, Gerlach M, Warnke A, Herpertz-Dahlmann B, Gründemann D, Grimberg G, Schulz E, Remschmidt H, Wewetzer C, Schömig E.

Int J Neuropsychopharmacol. 2008 Feb;11(1):35-48. Epub 2007 May 4.

PMID:
17477885
48.

Population pharmacokinetics of the BEACOPP polychemotherapy regimen in Hodgkin's lymphoma and its effect on myelotoxicity.

Wilde S, Jetter A, Rietbrock S, Kasel D, Engert A, Josting A, Klimm B, Hempel G, Reif S, Jaehde U, Merkel U, Busse D, Schwab M, Diehl V, Fuhr U.

Clin Pharmacokinet. 2007;46(4):319-33.

PMID:
17375983
49.

Plasma and tissue pharmacokinetics of epirubicin and Paclitaxel in patients receiving neoadjuvant chemotherapy for locally advanced primary breast cancer.

Hunz M, Jetter A, Warm M, Pantke E, Tuscher M, Hempel G, Jaehde U, Untch M, Kurbacher C, Fuhr U.

Clin Pharmacol Ther. 2007 May;81(5):659-68. Epub 2007 Feb 14.

PMID:
17301739
50.

Supplemental Content

Loading ...
Support Center